Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{67dd91bbd4574c54aaad0308bc5acb45,
title = "Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis",
abstract = "Antineutrophil cytoplasm antibody associated systemic vasculitides (AASV) have traditionally been managed with a combination of cyclophosphamide and glucocorticoids during the induction phase, followed by azathioprine in the maintenance phase. Whilst these therapies have markedly improved the prognosis in AASV, treatment related adverse events remain a major challenge and include complications such as infection, glucocorticoid related side effects, malignancy, cardiovascular disease, infertility and death. Newer biologic therapies have been shown to demonstrate equivalent efficacy as cyclophosphamide for remission but the hoped for reduction in adverse events has yet to be realised. More recent efforts have been focused on refining existing therapeutic regimens and strategies, tailoring individual treatment to disease severity, patient age and kidney function to derive maximum treatment efficacy while minimising treatment toxicity. In particular, current interventional trials are targeting a reduction in corticosteroid exposure in an effort to make induction and maintenance regimens safer.",
keywords = "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Drug-Related Side Effects and Adverse Reactions, Glucocorticoids, Humans, Immunosuppressive Agents, Prognosis, Severity of Illness Index",
author = "Limy Wong and Lorraine Harper and Little, {Mark A}",
note = "{\textcopyright} The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.",
year = "2015",
month = apr
doi = "10.1093/ndt/gfu406",
language = "English",
volume = "30 Suppl 1",
pages = "i164--70",
journal = "Nephrology, Dialysis, Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - Getting the balance right

T2 - adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis

AU - Wong, Limy

AU - Harper, Lorraine

AU - Little, Mark A

N1 - © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

PY - 2015/4

Y1 - 2015/4

N2 - Antineutrophil cytoplasm antibody associated systemic vasculitides (AASV) have traditionally been managed with a combination of cyclophosphamide and glucocorticoids during the induction phase, followed by azathioprine in the maintenance phase. Whilst these therapies have markedly improved the prognosis in AASV, treatment related adverse events remain a major challenge and include complications such as infection, glucocorticoid related side effects, malignancy, cardiovascular disease, infertility and death. Newer biologic therapies have been shown to demonstrate equivalent efficacy as cyclophosphamide for remission but the hoped for reduction in adverse events has yet to be realised. More recent efforts have been focused on refining existing therapeutic regimens and strategies, tailoring individual treatment to disease severity, patient age and kidney function to derive maximum treatment efficacy while minimising treatment toxicity. In particular, current interventional trials are targeting a reduction in corticosteroid exposure in an effort to make induction and maintenance regimens safer.

AB - Antineutrophil cytoplasm antibody associated systemic vasculitides (AASV) have traditionally been managed with a combination of cyclophosphamide and glucocorticoids during the induction phase, followed by azathioprine in the maintenance phase. Whilst these therapies have markedly improved the prognosis in AASV, treatment related adverse events remain a major challenge and include complications such as infection, glucocorticoid related side effects, malignancy, cardiovascular disease, infertility and death. Newer biologic therapies have been shown to demonstrate equivalent efficacy as cyclophosphamide for remission but the hoped for reduction in adverse events has yet to be realised. More recent efforts have been focused on refining existing therapeutic regimens and strategies, tailoring individual treatment to disease severity, patient age and kidney function to derive maximum treatment efficacy while minimising treatment toxicity. In particular, current interventional trials are targeting a reduction in corticosteroid exposure in an effort to make induction and maintenance regimens safer.

KW - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

KW - Drug-Related Side Effects and Adverse Reactions

KW - Glucocorticoids

KW - Humans

KW - Immunosuppressive Agents

KW - Prognosis

KW - Severity of Illness Index

U2 - 10.1093/ndt/gfu406

DO - 10.1093/ndt/gfu406

M3 - Article

C2 - 25583294

VL - 30 Suppl 1

SP - i164-70

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

SN - 0931-0509

ER -